Skip to main content

Table 1 Sociodemographic and clinical characteristics of the study subjects

From: Independent risk factors for axillary lymph node metastasis in breast cancer patients with one or two positive sentinel lymph nodes

N (%) Patients with one or two SLNs (n = 389)
Variable Characteristics Negative ALN (n = 215) Positive ALN (n = 174) x2/Z P
Demographic
X1 Age     
< 60 162 (75.3) 146 (83.9) 4.2734 0.0387
≥60 53 (24.7) 28 (16.1)   
 X2 Occupation     
Manual labor 96 (44.7) 95 (54.6) 4.9281 0.0851
Mental work 51 (23.7) 40 (23.0)   
Other 68 (31.6) 39 (22.4)   
 X3 Menarchea     
< 15 148 (68.8) 110 (63.2) 1.6259 0.2023
≥15 52 (0.24) 52 (29.9)   
 X4 Menopausal status     
Premenopausal 121 (56.3) 98 (56.3) 0.0001 0.9933
postmenopausal 94 (43.7) 76 (43.7)   
Clinical Characteristics
 X5 Delay in diagnosis (days)a     
0–90 86 (40.0) 68 (39.1) 0.0168 0.9866
91–180 49 (22.8) 39 (22.4)   
181–365 28 (13.0) 29 (16.7)   
> 366 51 (23.7) 37 (21.3)   
 X6 Tumor primary site     
Right 119 (55.3) 80 (46.0) 3.3805 0.066
Left 96 (44.7) 94 (54.0)   
 X7 Tumor locationa     
Upper Outer 125 (58.1) 113 (64.9) 5.2315 0.1556
Lower Outer 34 (15.8) 30 (17.2)   
Upper Inner 41 (19.1) 19 (10.9)   
Lower Inner 12 (5.6) 12 (6.9)   
 X8 Tumor Sizea     
≤2 cm 89 (41.4) 75 (43.1) 0.0299 0.8626
>  2 cm 112 (52.1) 91 (52.3)   
 X9 Pathological typea     
IDC 199 (92.6) 159 (91.4) 0.1822 0.6695
Other 16 (74.4) 15 (8.62)   
 X10 ERa     
(−) 42 (19.5) 36 (20.7) 0.0614 0.8043
(+) 169 (78.6) 136 (78.2)   
 X11 PRa     
(−) 66 (30.7) 55 (31.6) 0.0213 0.8839
(+) 145 (67.4) 117 (67.2)   
 X12 HER-2a     
(−) 137 106 0.0303 0.8618
(+) 38 28   
 X13 Triple negativea     
Yes 15 (6.98) 14 (8.00) 0.1933 0.6601
No 188 (87.4) 148 (85.1)   
 X14 Ki-67a     
(low) 164 (76.3) 133 (76.4) 0.0521 0.8195
(high) 47 (21.9) 36 (20.7)   
 X15 Tumor Gradea     
1 28 (13.0) 18 (10.3) 0.5895 0.5555
2 73 (34.0) 59 (33.9)   
3 114 (53.0) 95 (54.6)   
 X16 Postoperative ALNsa     
0–10 55 (25.6) 53 (30.5) −0.0294 0.9765
11–19 136 (63.3) 94 (54.0)   
≥20 19 (8.8) 25 (14.4)   
X17 Ratio of positive to total SLNsa     
< 0.5 155 (72.1) 86 (49.4) 20.4071 < 0.0001
≥0.5 60 (28.0) 87 (50.0)   
  1. Abbreviations: ER estrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor-2, SLN sentinel lymph node, ALN axillary lymph node, IDC invasive ductal carcinoma, SD standard deviation. aMissing data: Menarche (n = 27); Delay in diagnosis (days) (n = 2); Tumor primary quadrant (n = 3); estrogen receptor (ER) (n = 6); Progesterone receptor (PR) (n = 6), Her-2 (n = 12); Ki-67 (n = 8); Tumor size (n = 22); Triple negative (n = 24); Tumor grade (n = 2); Ratio of positive to total SLNs (n = 1); and postoperative ALNs (n = 3). All lymph nodes were examined with hematoxylin and eosin (H&E) staining. Her-2 positivity was defined as a score of 3+ or ≤ 2+ combined with an application on fluorescence in situ hybridization (FISH). The molecular subtypes were determined according to the criteria by the World Health Organization